Lipocine Inc (LPCN)

$7.15 -0.16 (-2.19%)
Market Cap 52.19M
Revenue (ttm) 1.98M
Net Income (ttm) -9.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -486.36%
Debt to Equity Ratio 0.00
Volume 79,300
Avg Vol 131,706
Day's Range N/A - N/A
Shares Out 7.30M
Stochastic %K 10%
Beta 0.98
Analysts Sell
Price Target $13.00

Company Profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone...

Industry: Biotechnology
Sector: Healthcare
Phone: 801 994 7383
Fax: 801 994 7388
Address:
675 Arapeen Drive, Suite 202, Salt Lake City, United States
LamboRush
LamboRush Mar. 21 at 4:52 PM
$LPCN
0 · Reply
LisaTaylora
LisaTaylora Mar. 21 at 4:34 PM
$CVKD Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-highlights-research-supporting-12-lox-mbmap9qco4op.html $TBT $LPCN $VICR $SLB
1 · Reply
BioAB
BioAB Mar. 21 at 4:19 PM
$LPCN
1 · Reply
brunoq14
brunoq14 Mar. 20 at 9:38 AM
$LPCN Recent guidance has been pretty specific. Nothing likely until April. I don't have a very large position. Probably will just hold and await further developments.
1 · Reply
ITF
ITF Mar. 19 at 11:47 PM
$LPCN Current market = artificially small Right now, the postpartum depression (PPD) drug market is tiny relative to need: • ~$260M total market (major countries)  • Only ~720k diagnosed cases in the U.S., ~1.3M globally  • But ~500k U.S. women actually experience PPD annually Translation: Most women aren’t getting treated with these drugs at all Why? Because current options suck: • IV infusion (hospital stay) • Expensive • Logistically hard after childbirth 2. Oral treatment = unlocking “hidden demand” This is the key shift. An oral drug like LPCN 1154 could: Expand treatment from: • Severe cases only (hospital-level) To: • Moderate + severe • Outpatient • Much earlier intervention
2 · Reply
ITF
ITF Mar. 19 at 8:24 PM
$LPCN PPD is one of those proboems that most of it's patiants are hidin or unspoken , most weman that suffer ppd are ashamed or unaware of the severty of their problem and yet still there is a large market for treatment , even if rersults are just good not even fantastic i expect a huge spike , becuase once the realization hits that there is an oral cure you can take at home in the years to come it will be like solving a headache - so any result that will extract the "shame" caused by ppd and bring the solution home and make it simple would adress a huge multiply of the market cap its based on right now. go LPCN
1 · Reply
amazingcrwns
amazingcrwns Mar. 19 at 5:31 PM
$LPCN This is not what I was expecting this close to the phase 3 readout.
1 · Reply
FuzzBuzz
FuzzBuzz Mar. 19 at 2:45 PM
$LPCN cautiously adding shares on these pullbacks…but it seems more and more likely it’ll be a sell the news event when the data comes out. Too much risk and uncertainty with the Iran war for investors to hold risky assets atm. Hopefully I’m wrong, but after being in this stock for a couple of years, it’s just difficult to be really optimistic
3 · Reply
BioPM1989
BioPM1989 Mar. 18 at 1:09 AM
$LPCN
1 · Reply
Tothemoonemoji
Tothemoonemoji Mar. 17 at 4:41 PM
$LPCN Price target raise from Alliance to 11. Seems meaningless. Results are great, gonna fly. Suck, it'll tank. Pretty binary
1 · Reply
Latest News on LPCN
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Mar 10, 2026, 8:00 AM EDT - 11 days ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2025

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)

Feb 18, 2026, 8:00 AM EST - 4 weeks ago

Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD)

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Jan 20, 2026, 8:00 AM EST - 2 months ago

Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Jan 12, 2026, 8:00 AM EST - 2 months ago

Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Dec 16, 2025, 8:00 AM EST - 3 months ago

Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Nov 18, 2025, 8:00 AM EST - 4 months ago

Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Nov 6, 2025, 8:00 AM EST - 4 months ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Nov 4, 2025, 8:00 AM EST - 4 months ago

Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

Sep 30, 2025, 8:00 AM EDT - 6 months ago

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 4:30 PM EDT - 7 months ago

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Aug 26, 2025, 8:00 AM EDT - 7 months ago

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Aug 5, 2025, 8:00 AM EDT - 8 months ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Jun 26, 2025, 8:00 AM EDT - 9 months ago

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Jun 23, 2025, 8:00 AM EDT - 9 months ago

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

Jun 9, 2025, 8:00 AM EDT - 10 months ago

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

May 22, 2025, 8:00 AM EDT - 10 months ago

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

May 14, 2025, 8:00 AM EDT - 11 months ago

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

May 8, 2025, 8:00 AM EDT - 11 months ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

May 6, 2025, 8:00 AM EDT - 11 months ago

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Mar 26, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Lipocine Announces FDA Labeling Changes for Testosterone Products

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Lipocine Announces FDA Labeling Changes for Testosterone Products

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Feb 6, 2025, 8:00 AM EST - 1 year ago

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Dec 17, 2024, 8:00 AM EST - 1 year ago

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Nov 18, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

May 8, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

May 1, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Apr 11, 2024, 7:00 AM EDT - 2 years ago

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Mar 7, 2024, 8:00 AM EST - 2 years ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Lipocine to Present at 36th Annual Roth Conference

Mar 6, 2024, 8:00 AM EST - 2 years ago

Lipocine to Present at 36th Annual Roth Conference

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

Feb 6, 2024, 8:00 AM EST - 2 years ago

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

Feb 2, 2024, 8:00 AM EST - 2 years ago

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Jan 18, 2024, 8:00 AM EST - 2 years ago

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Lipocine to Present at Biotech Showcase 2024

Dec 19, 2023, 8:00 AM EST - 2 years ago

Lipocine to Present at Biotech Showcase 2024

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

Nov 13, 2023, 2:45 PM EST - 2 years ago

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

Nov 8, 2023, 8:00 AM EST - 2 years ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

LamboRush
LamboRush Mar. 21 at 4:52 PM
$LPCN
0 · Reply
LisaTaylora
LisaTaylora Mar. 21 at 4:34 PM
$CVKD Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-highlights-research-supporting-12-lox-mbmap9qco4op.html $TBT $LPCN $VICR $SLB
1 · Reply
BioAB
BioAB Mar. 21 at 4:19 PM
$LPCN
1 · Reply
brunoq14
brunoq14 Mar. 20 at 9:38 AM
$LPCN Recent guidance has been pretty specific. Nothing likely until April. I don't have a very large position. Probably will just hold and await further developments.
1 · Reply
ITF
ITF Mar. 19 at 11:47 PM
$LPCN Current market = artificially small Right now, the postpartum depression (PPD) drug market is tiny relative to need: • ~$260M total market (major countries)  • Only ~720k diagnosed cases in the U.S., ~1.3M globally  • But ~500k U.S. women actually experience PPD annually Translation: Most women aren’t getting treated with these drugs at all Why? Because current options suck: • IV infusion (hospital stay) • Expensive • Logistically hard after childbirth 2. Oral treatment = unlocking “hidden demand” This is the key shift. An oral drug like LPCN 1154 could: Expand treatment from: • Severe cases only (hospital-level) To: • Moderate + severe • Outpatient • Much earlier intervention
2 · Reply
ITF
ITF Mar. 19 at 8:24 PM
$LPCN PPD is one of those proboems that most of it's patiants are hidin or unspoken , most weman that suffer ppd are ashamed or unaware of the severty of their problem and yet still there is a large market for treatment , even if rersults are just good not even fantastic i expect a huge spike , becuase once the realization hits that there is an oral cure you can take at home in the years to come it will be like solving a headache - so any result that will extract the "shame" caused by ppd and bring the solution home and make it simple would adress a huge multiply of the market cap its based on right now. go LPCN
1 · Reply
amazingcrwns
amazingcrwns Mar. 19 at 5:31 PM
$LPCN This is not what I was expecting this close to the phase 3 readout.
1 · Reply
FuzzBuzz
FuzzBuzz Mar. 19 at 2:45 PM
$LPCN cautiously adding shares on these pullbacks…but it seems more and more likely it’ll be a sell the news event when the data comes out. Too much risk and uncertainty with the Iran war for investors to hold risky assets atm. Hopefully I’m wrong, but after being in this stock for a couple of years, it’s just difficult to be really optimistic
3 · Reply
BioPM1989
BioPM1989 Mar. 18 at 1:09 AM
$LPCN
1 · Reply
Tothemoonemoji
Tothemoonemoji Mar. 17 at 4:41 PM
$LPCN Price target raise from Alliance to 11. Seems meaningless. Results are great, gonna fly. Suck, it'll tank. Pretty binary
1 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 17 at 11:30 AM
$LPCN Q4 '25 Earnings Results & Recap Lipocine Inc. reported a net loss of $9,627,505 for the year ended December 31, 2025, with total revenues decreasing to $2M from $11.2M in 2024, and cash reserves falling to $14.9M.
1 · Reply
Tothemoonemoji
Tothemoonemoji Mar. 16 at 7:31 PM
$LPCN 10k ask at 7.55. And this keeps dipping. Need those results fast
0 · Reply
BioAB
BioAB Mar. 16 at 4:07 PM
$LPCN I had like 130k shares pre split bought at $1.13 ish avg, i forget exact, I ended up with somewhere around 13k or something and 12$ - it’s been a long while I don’t remember details, and I bought another 47k shares much lower, with biggest buys around 2-4s. 🤣🤣🤣 @hiwatt and have sold in 8-10$ mostly.
0 · Reply
BioAB
BioAB Mar. 16 at 4:04 PM
$LPCN clowns on ymb nick, @hiwatt , angel. Think i sold at loss, 🤣🤣🤣🤣 Anyways, my sale has nothing to do with prospects of the company. I’ll be right back here asap. Nothing has changed fundementally and any dilution is well worth it here. Better negotiations or even a larger pie in the talks for 1154.
1 · Reply
HoHoHoHum
HoHoHoHum Mar. 16 at 10:31 AM
$LPCN there is a lot of nervousness and negativity lately. Some bearish posters have reemerged as well. Well, I can understand with the recent ATM activity and the 1154 confirmatory trial results to come out in a few weeks. Agree it can always go either way. But to me it is also a technical adjustment to the sharp rise that began on Jan 2. We in fact, touched that point on Friday and bounced in after hours. I see this as an opportunity refill some of the shares I sold close to 11. Yes risk is always there and the company was managing its own risk by selling using atm after a spike. Everyone has to manage their own risk. I remain positive.
3 · Reply
NothnSpecial
NothnSpecial Mar. 15 at 12:15 PM
$LPCN don’t see any news to cause that spike down. I have been waiting for sub 8 to pick up a few more.
0 · Reply
BioAB
BioAB Mar. 14 at 2:09 PM
$LPCN after 5+ years, I sold all my shares. At around 8-10ish. Was profitable despite the R/S. GLTA. Been trading a few other stocks.
5 · Reply
WallStreetBuyDip
WallStreetBuyDip Mar. 14 at 3:19 AM
$LPCN Massive volume spike on Mar 13 with 163,547 shares traded, way above the 66,428 average volume. Price stayed at $7.34. Recent price fluctuation from $8.99 to $8.05 and back down. Considering waiting for a lower H% before jumping in.
0 · Reply
History101
History101 Mar. 13 at 10:59 PM
$LPCN bs dump at the end of the day...
0 · Reply
spyrogyra
spyrogyra Mar. 13 at 9:47 PM
$LPCN https://www.prnewswire.com/news-releases/lipocine-announces-last-patient-last-visit-in-pivotal-phase-3-trial-of-lpcn-1154-for-postpartum-depression-ppd-302691331.html?utm_source=chatgpt.com
2 · Reply
FBP
FBP Mar. 13 at 9:14 PM
$LPCN wow this came back from dead
0 · Reply
amazingcrwns
amazingcrwns Mar. 13 at 8:22 PM
$LPCN
0 · Reply